Tetra Bio-Pharma incorporated Dr. Louis-Philippe de Lorimier into their clinical advisory board for the veterinary market.
“We are leveraging our current R&D work in humans to accelerate the development of the first cannabinoid-based drug for pets in the cancer-associated supportive therapy market, including pain. This market is underserved and patients and their owner are waiting for alternatives that are safer, more tolerable and more efficacious. We believe that our collaboration with Dr. de Lorimier will bring significant contributions to the launch of the first Health Canada approved drug for pets using cannabinoid-based active ingredients,” states Dr. Guy Chamberland, Chief Scientific Officer (CSO) of Tetra.
Once approved, the trial will be run at private veterinary clinics across Canada, which treats tens of thousands of animals every year.